Psychostimulant-induced attenuation of hyperactivity and prepulse inhibition deficits in Adcyap1-deficient mice

Journal of Neuroscience

Volumn 26, Issue 19, 2006, Pages 5091-5097

  Tanaka, Kazuhiro ^a   Shintani, Norihito ^a   Hashimoto, Hitoshi ^a   Kawagishi, Naofumi ^a   Ago, Yukio ^a   Matsuda, Toshio ^a   Hashimoto, Ryota ^b   Kunugi, Hiroshi ^b   Yamamoto, Akiko ^a   Kawaguchi, Chihiro ^a   Shimada, Takeshi ^a   Baba, Akemichi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

Hyperactivity; Knock out mice; Neuropeptide; Prepulse inhibition; Psychostimulant; Serotonin 5 HT1A receptor

Indexed keywords

2 DIBUTYLAMINO 8 HYDROXYTETRALIN; ADENYLATE CYCLASE ACTIVATOR; AMPHETAMINE; HALOPERIDOL; NEUROPEPTIDE; PROTEIN ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; PROTEIN C FOS; PSYCHOSTIMULANT AGENT; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG; ADCYAP1 PROTEIN, MOUSE; CENTRAL STIMULANT AGENT; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HYPERACTIVITY; LOCOMOTION; MOUSE; NERVE CELL; NONHUMAN; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; SENSORIMOTOR CORTEX; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; AUDITORY STIMULATION; HYPERKINESIA; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; REACTION TIME; STARTLE REFLEX;

ACOUSTIC STIMULATION; AMPHETAMINE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; HYPERKINESIS; MICE; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; REACTION TIME; STARTLE REACTION;

EID: 33646918578     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4376-05.2006     Document Type: Article

References (46)

1. 1A receptor density and 8-OH-DPAT-induced hypothermia: blockade by drugs preventing 5-hydroxytryptamine depletion. Eur J Pharmacol 346:181-188.
2. Arimura A (1998) Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. J Physiol (Japan) 48:301-331.
3. Badiani A, Oates MM, Day HE, Watson SJ, Akil H, Robinson TE (1998) Amphetamine-induced behavior, dopamine release, and c-fos mRNA expression: modulation by environmental novelty. J Neurosci 18:10579-10593.
4. Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152.
5. Barr AM, Lehmann-Masten V, Paulus M, Gainetdinov RR, Caron MG, Geyer MA (2004) The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. Neuropsychopharmacology 29:221-228.
6. 1A autoreceptor is an important pharmacological target for the modulation of cocaine behavioral stimulant effects. Brain Res 1034:162-171.
7. Castellanos FX, Tannock R (2002) Neuroscience of attention-deficit/ hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci 3:617-628.
8. Castellanos FX, Fine EJ, Kaysen D, Marsh WL, Rapoport JL, Hallett M (1996) Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biol Psychiatry 39:33-41.
9. Colwell CS, Michel S, Itri J, Rodriguez W, Tam J, Lelievre V, Hu Z, Waschek JA (2004) Selective deficits in the circadian light response in mice lacking PACAP. Am J Physiol Regul Integr Comp Physiol 287:R1194-R1201.
10. Davids E, Zhang K, Tarazi FI, Baldessarini RJ (2003) Animal models of attention-deficit hyperactivity disorder. Brain Res Brain Res Rev 42:1-21.
11. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. San Diego: Academic.
12. Gainetdinov RR, Caron MG (2000) An animal model of attention deficit hyperactivity disorder. Mol Med Today 6:43-44.
13. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG (1999) Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283:397-401.
14. Garland M, Kirkpatrick P (2004) Atomoxetine hydrochloride. Nat Rev Drug Discov 3:385-386.
15. Geyer MA (1996) Serotonergic functions in arousal and motor activity. Behav Brain Res 73:31-35.
16. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156:117-154.
17. 1 receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 31:295-301.
18. Gray SL, Cummings KJ, Jirik FR, Sherwood NM (2001) Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism. Mol Endocrinol 15:1739-1747.
19. Hamelink C, Tjurmina O, Damadzic R, Young WS, Weihe E, Lee HW, Eiden LE (2002) Pituitary adenylate cyclase-activating polypeptide is a sympathoadrenal neurotransmitter involved in catecholamine regulation and glucohomeostasis. Proc Natl Acad Sci USA 99:461-466.
20. Hashimoto H, Nogi H, Mori K, Ohishi H, Shigemoto R, Yamamoto K, Matsuda T, Mizuno N, Nagata S, Baba A (1996) Distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide receptor in the rat brain: an in situ hybridization study. J Comp Neurol 371:567-577.
21. Hashimoto H, Shintani N, Tanaka K, Mori W, Hirose M, Matsuda T, Sakaue M, Miyazaki J, Niwa H, Tashiro F, Yamamoto K, Koga K, Tomimoto S, Kunugi A, Suetake S, Baba A (2001) Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). Proc Natl Acad Sci USA 98:13355-13360.
22. Hashimoto H, Shintani N, Baba A (2006) New insights into the central PACAPergic system from the phenotypes in PACAP- and PACAP receptor-knockout mice. Ann NY Acad Sci, in press.
23. Hawk Jr LW, Yartz AR, Pelham Jr WE, Lock TM (2003) The effects of methylphenidate on prepulse inhibition during attended and ignored prestimuli among boys with attention-deficit hyperactivity disorder. Psychopharmacology 165:118-127.
24. Kawaguchi C, Tanaka K, Isojima Y, Shintani N, Hashimoto H, Baba A, Nagai K (2003) Changes in light-induced phase shift of circadian rhythm in mice lacking PACAP. Biochem Biophys Res Commun 310:169-175.
25. Lipska BK, Weinberger DR (2000) To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23:223-239.
26. Liu GJ, Madsen BW (1997) PACAP38 modulates activity of NMDA receptors in cultured chick cortical neurons. J Neurophysiol 78:2231-2234.
27. Lucki I (1998) The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44:151-162.
28. Mabuchi T, Shintani N, Matsumura S, Okuda-Ashitaka E, Hashimoto H, Muratani T, Minami T, Baba A, Ito S (2004) Pituitary adenylate cyclase-activating polypeptide is required for the development of spinal sensitization and induction of neuropathic pain. J Neurosci 24:7283-7291.
29. Masuo Y, Suzuki N, Matsumoto H, Tokito F, Matsumoto Y, Tsuda M, Fujino M (1993) Regional distribution of pituitary adenylate cyclase activating polypeptide (PACAP) in the rat central nervous system as determined by sandwich-enzyme immunoassay. Brain Res 602:57-63.
30. Ornitz EM, Guthrie D, Lane SJ, Sugiyama T (1990) Maturation of startle facilitation by sustained prestimulation. Psychophysiology 27:298-308.
31. Pellegri G, Magistretti PJ, Martin JL (1998) VIP and PACAP potentiate the action of glutamate on BDNF expression in mouse cortical neurones. Eur J Neurosci 10:272-280.
32. Piggins HD, Stamp JA, Burns J, Rusak B, Semba K (1996) Distribution of pituitary adenylate cyclase activating polypeptide (PACAP) immunoreactivity in the hypothalamus and extended amygdala of the rat. J Comp Neurol 376:278-294.
33. Popper CW (2000) Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 9:605-646.
34. 1A receptors attenuates the locomotor, but not the discriminative, effects of amphetamine and cocaine in rats. Behav Pharmacol 8:699-706.
35. Przegalinski E, Siwanowicz J, Baran L, Filip M (2000) Activation of serotonin (5-HT)1A receptors inhibits amphetamine sensitization in mice. Life Sci 66:1011-1019.
36. 2 receptor antagonists. J Neurosci 21:305-313.
37. Ralph RJ, Paulus MP, Geyer MA (2001b) Strain-specific effects of amphetamine on prepulse inhibition and patterns of locomotor behavior in mice. J Pharmacol Exp Ther 298:148-155.
38. 1A receptor agonist MKC-242 reverses isolation rearing-induced deficits of prepulse inhibition in mice. Psychopharmacology 170:73-79.
39. Shintani N, Mori W, Hashimoto H, Imai M, Tanaka K, Tomimoto S, Hirose M, Kawaguchi C, Baba A (2002) Defects in reproductive functions in PACAP-deficient female mice. Regul Pept 109:45-48.
40. Solanto MV (1998) Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 94:127-152.
41. Solanto MV (2002) Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res 130:65-71.
42. Stella N, Magistretti PJ (1996) Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) potentiate the glutamate-evoked release of arachidonic acid from mouse cortical neurons. Evidence for a cAMP-independent mechanism. J Biol Chem 271:23705-23710.
43. Swerdlow NR, Geyer MA (1998) Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24:285-301.
44. Tanaka K, Hashimoto H, Shintani N, Yamamoto A, Baba A (2004) Reduced hypothermic and hypnotic responses to ethanol in PACAP-deficient mice. Regul Pept 123:95-98.
45. Usdin TB, Bonner TI, Mezey E (1994) Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135:2662-2680.
46. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52:269-324.